Projects

ProjectsItalian Version

 

Date Title Synopsis and Results Proposer
2022-06-15 Early prediction of unfavorable evolution of Clinically Isolated Syndrome (CIS) patients ...
read more
Roberto Bergamaschi
2022-05-26 Clinical characteristics and disease outcomes of late onset Multiple Sclerosis: a retrospective multicenter study. ...
read more
Lorena Lorefice
2022-05-26 Comparative effectiveness of different Natalizumab dosing schedules in real world life: a retrospective Italian multicentre study ...
read more
Francesco Patti
2022-05-26 Comparative effectiveness of initial Treatment Choices for Multiple Sclerosis: a multicentre study ...
read more
Emanuele D'Amico
2022-05-26 Exploring phenotype and recovery from relapses in relapsing-remitting multiple sclerosis patients: old versus new Disease-Modifying Therapies ...
read more
Emanuele D'Amico
2022-05-26 Demographic, clinical and treatment factors associated with the risk and severity of Covid-19 in people with Multiple Sclerosis ...
read more
Maria Trojano
2022-05-26 HETEROGENEITY Study. Are multiple sclerosis (MS) phenotypes influenced by the type of referral MS center? ...
read more
Roberto Bergamaschi
2022-04-26 Silent progression in an Italian CIS and Relapsing-Remitting MS cohort Objectives. To analyze, in a big Italian multicentric cohort of CIS and RRMS patients, data regarding the silent disease progression independent from relapse activity and MRI data, comparing treated - with "platform" and "highly active" therapies - and untreated patients. Methods. Patients with: age >18 years; a CIS or RRMS diagnosis made using the ...
read more
Maria Pia Amato - Bellinvia
2021-12-31 Big Multiple Sclerosis Data (BMSD) network ...
read more
Maria Trojano
2021-12-31 Autologous Hematopoietic Stem Cell Transplantation For Secondary Progressive Multiple Sclerosis: a comparative study with matched control patients from the Italian Multiple Sclerosis Register ...
read more
Matilde Inglese
2021-12-31 Assessing early clinical and MRI predictors of treatment response in pediatric multiple sclerosis patients. ...
read more
Maria Pia Amato/De Meo
2021-10-28 EPID-MS Evaluation of the drivers of the therapy switch in active RRMS and active SPMS patients. ...
read more
Maria Trojano-Pietro Iaffaldano
2020-11-01 Assessing Efficacy and Safety of treatments in progressive Multiple Sclerosis Except for Ocrelizumab, previous phase-III randomized controlled trials largely failed in finding benefit of disease modifying drugs (DMDs) among patients affected by primary progressive multiple sclerosis (PPMS). Consistently with these findings, most of the Real word studies drove to the same conclusion, finding no substantial differences between ...
read more
Maria Pia Amato
2020-10-15 E-MUSIC: Early MUltiple Sclerosis Italian Cohort Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) that is characterized by inflammation, demyelination, and degenerative changes. Most individuals are diagnosed with MS at age 20–40 years. Pediatric-onset MS (POMS), before the age of 18, represents 3-10% of the whole MS population, while late-onset ...
read more
Maria Pia Amato-Mattia Fonderico
2020-09-15 Predictive factors of disability progression in a large cohort of italian multiple sclerosis patients Multiple sclerosis (MS) is one of the most common cause of neurological disability in young adults globally. It is a chronic degenerative illness and therefore carries a high economic and quality of life burden associated with it. One of the principal objectives in the care of people with MS is, therefore, to reduce the irreversible accumulation of ...
read more
Marzia Romeo
2020-07-15 INTEREST. Italian Multiple Sclerosis Registry non interventional retrospective analysis in secondary progressive multiple sclerosis The distinction between relapsing-remitting (RR) MS and progressive phenotypes remains a critical challenge for the neurologist in real clinical practice: currently there are not specific parameters or validated biomarkers to address the diagnostic doubt, which remains entrusted to clinical experience. In fact, in clinical practice secondary progre ...
read more
Maria Trojano
2020-06-15 Retrospective pilot study on long-term Cladribine effects in patients with relapsing remitting multiple sclerosis or clinically isolated syndrome. The aim of this Italian pilot study call CLARINET-MS study is to explore the feasibility of the retrospective approach for evaluating effectiveness in subjects previously treated with Cladribine and then followed as per clinical practice. The CLARINET-MS study assessed the long-term effectiveness of cladribine tablets by following patients with mu ...
read more
Francesco Patti
2020-06-15 Early-aggressive treatment algorithm versus classical escalation therapy in relapsing Multiple Sclerosis The most important goal of multiple sclerosis (MS) therapy is the prevention of long-term disability accumulation. The therapeutic scenario for relapsing–remitting MS (RRMS) has widely expanded during the past 20 years. Choosing the MS therapy has become increasingly complex, due to the difficulties in weighing the risk/benefit ratio of several dif ...
read more
Maria Trojano-Pietro Iaffaldano
2020-06-15 Risks associated with Wash-Out Duration when switching from Fingolimod to cell-depleting agents Decisions regarding the duration of washout periods between disease-modifying therapies (DMTs) in multiple sclerosis (MS) patients need to take both the risk of disease reactivation and safety issues regarding overlapping immunological mechanisms of action into account. Fingolimod is an oral DMT, approved for the treatment of highly active relapsin ...
read more
Diana Ferraro
2020-06-15 Assessing the clinical course of pediatric onset multiple sclerosis in different treatment eras: are we really modifying the disease? Availability of new disease modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear if this improvement also involves pediatric-onset MS (POMS) patients, whose early management is limited by a low number of approved DMTs and, possibly, othe ...
read more
Damiano Baroncini
2020-04-24 The use of a roving EDSS reference value to enhance detection of EDSS worsening events: A real world evaluation through the Italian MS Register. Disease registries are recognized as providing meaningful information on the burden, natural history, and long-term safety and effectiveness of treatments for patients with chronic diseases. Data collected in a register are also useful for observational research on sample populations treated and followed in real-world conditions. The result provide ...
read more
Paola Mosconi
2019-12-15 Retrospective study to evaluate the long-term impact of different treatment strategies on disability outcomes in patients with Relapsing Multiple Sclerosis. Italian IMedWeb MS Registry. RE.LO.DI.MS Study The increase in disease-modifying drugs (DMDs) allows individualization of treatment in relapsing multiple sclerosis (RMS); however, the long-term impact of different treatment sequences is not well established. This is particularly relevant for MS patients who may need to postpone more aggressive DMD strategies. To evaluate different therapeutic s ...
read more
Damiano Paolicelli
2019-06-15 INSPIRA - Italian analysis of the National multiple sclerosis registry Studying the concept of Progression Independent from Relapse Activity To date, secondary-progressive multiple sclerosis (SPMS) is diagnosed retrospectively by neurologists, according to the Lublin’ definition: a history of a gradual disability progression, independent of relapses, after an initial relapsing course. No biological nor clinical markers are available to make more sensitive and reliable the identification ...
read more
Maria Trojano-Pietro Iaffaldano
2017-10-14 Profiling treatment choices in MS during two different eras: a real world assessment in the Italian MS Registry The treatment options for people with multiple sclerosis (MS) have expanded dramatically during the past 20 years. The objective of these disease-modifying treatments (DMTs) is the prevention of further relapses and accumulation of disability. In the European Union neurologists and patients can currently choose from different licensed DMTs, making ...
read more
Maria Trojano-Pietro Iaffaldano

Privacy Policy

FISM Fondazione Italiana Sclerosi Multipla Onlus - Registered Office Via Operai 40, 16149 Genova - CF 95051730109